Nasdaq:US$13.02 (-0.38) | HKEX:HK$20.65 (-0.65) | AIM:£2.20 (+0.03)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors